Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Dyne Therapeutics, Inc.NASDAQ: DYN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$173.4M, compared with -$110.26M a year earlier. Trailing-twelve-month EBITDA was -$495.35M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -38.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$173.4M-49.4% QoQ
- Last fiscal yearDec 2025
- -$437.97M-38.7% YoY
- LTMJun 2026
- -$495.35M-20.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -57.3% | +100.0% | +157.3 pp |
| 1 year | -38.7% | +100.0% | +138.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (437.97M) USD
- Year-over-year change
- -38.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (437.97M) | -38.7% |
| FY2024 | 2024-12-31 | (315.75M) | -34.8% |
| FY2023 | 2023-12-31 | (234.26M) | -43.3% |
| FY2022 | 2022-12-31 | (163.5M) | -10.3% |
| FY2021 | 2021-12-31 | (148.2M) | — |
EBITDA vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's LTM Jun 2026 EBITDA of -$495.35M is the lowest of the 11 companies compared; the peer median is -$164.49M.
- Its year-over-year change of -20.6% is the 4th highest of 11, against a peer median of -71.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -$75.99M | +22.0% | — | — | |
| LTM Mar 2026 | -$164.11M | -405.9% | — | 511.5% | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$165.68M | -74.6% | — | — | |
| LTM Mar 2026 | -$174.59M | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$495.35M | -20.6% | — | — | |
| Peer median (excluding DYN) | -$164.49M | -71.5% | — | 146.3% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.46M | 2.24M | 2.05M |
| Gross Profit | 0 | 0 | (2.46M) | (2.24M) | (2.05M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Selling, General & Admin | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M |
| Operating Expenses | 150.03M | 170.96M | 239.7M | 341.64M | 466.14M |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| EBITDA | (148.2M) | (163.5M) | (234.26M) | (315.75M) | (437.97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (150.03M) | (170.96M) | (242.16M) | (343.89M) | (468.18M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 742K | 2.92M | 7.64M | 26.92M | 29.86M |
| Interest Expense | 0 | 2.92M | 0 | 0 | 6.19M |
| Other Income / Expenses | 734K | 2.86M | 6.23M | 26.47M | 21.97M |
| Income Before Tax | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| EPS (Diluted) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| Weighted Avg Shares | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
| Weighted Avg Shares (Diluted) | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.